180 Life announces publication of review on treatments for Dupuytren’s disease

180 Life Sciences announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery. In the publication, Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, and his colleague at the University of Oxford, describe the limitations for the current treatments for late-stage Dupuytren’s disease and the lack of evidence based on randomized double blind, placebo-controlled trials for treatments for early-stage disease, such as intranodular injection of steroid or radiotherapy. They go on to describe how tumor necrosis factor was identified as a potential therapeutic target through the study of cellular signaling mechanisms in tissue from patients. They also describe the results of the phase 2a dose ranging trial, which identified the most efficacious dose and formulation of adalimumab. This was followed by a phase 2b trial, which met the primary endpoint of reduction in nodule hardness and the secondary endpoint of decrease in nodule size, indicating the potential to control progression of early-stage disease.